2012

Marketing Plan
Claritine

Clara

Lorine

Neoday

Emilora

Lagadine

Loradad
Clara

Lorine

Neoday

Emilora

Lagadine

Loradad
Claritine

Clara

Lorine

Lorine

Tidlor

Neoday
Loradad

Emilora
Clara

Lorine

Lorine

Tidlor
Neoday

Loradad

Emilora
Claritine

Clara

Emilora

Lorine

Neoday
Lagadine
Claritine

Clara

Lorine

Lagadine

Neoday

Emilora
Claritine

Clara

Lorine

Neoday

Emilora

Lagadine

Loradad
Lorine

Lagadine

Neoday

Clara

Loratin

Loradad

Emilora
Claritine

Clara

Lorine

Loratin

Tidlor

Neoday

Lohist
Emilora
Claritine

Clara

Lorine

Neoday

Emilora

Lagadine

Loradad
Lorine

Loratin

Neoday

Clara

Loradad

Emilora
Clara

Claritine

Lorine

LoradaY

Lorine FM

Lagadine

Loramax

Glora
Clara

Lorine

Claritine

Lorahist

Loraday
Tidlor

Loramax
Lohist
Loradad

Glora
SWOT Analysis
Strengths Weaknesses
1. Emilora (Loratadine) is a 1. Emilora is a generic product
powerful non-sedating
antihistaminic
2. Emilora provides a high
antihistaminic effect in the
management of allergic rhinitis
and skin allergies Emilora is an
OTC product
3. Emilora provides a rapid onset of
action
4. Emilora provides a long
antihistaminic duration of action
5. Emilora ensure excellent patient
compliance because of once a
day dosage

EMILORA Training
 SWOT Analysis
Opportunities
1. Antihistamine Mkt is growing
fast
2. Trend & acceptance of Non
sedative antihistamine is on
continuous rise
3. Emilora has more effective
antihistaminic power compared
to Fexofenadine ( Tefast )
4. Price as well as profit margin of
Emilora are quite comfortable so
it has high potential to become
star product for our company
Threats
1. There are lot many generics in
the market
2. Increase comrtitir activities are
expected after our launch
3. We have another non sedating
antihistamine ( Glotrizine) so
there is possibility of
cannibalization
Sedating vs. Non-sedating Mkt.

EMILORA Training
Antihistamine
Rx Share per Disease
Main Prescribers
 Target Audience

Doctors Pharmacists Patients

GPs Private Adults

Pedia Pediatrics
Institutional

Derma

ENT
 Positioning

Emilora
,the 1st choice non sedating antihistamine for
all Respiratory & Skin allergies in adults &
Children
 Quantitative objectives
To achieve 2012 Forecasts with total value 2.120 M. Dhs (CIF)
With Grth 57%
Strategy

Apply a balanced push and pull strategy targeting

doctors, pharmacists and patient respectively,
while at the same time continuously hammering
up on its salient points like its once-daily dosing
schedule and non-sedating nature.
Promotional Activities
Brand Reminder
Em
ilo
ra
Papers Cubes in April

Brand reminder Apr. 2012 (5,000

@ 3Dhs)
 Promotional Activities
Brochure

(8,500 Brochures)